Developer docs
API playgroundTry for free, no card

Search company profiles

Pharma Research Bio

Full company profile

uuid000lwzm

Namestring
Pharma Research Bio
Legal namestring
주식회사 파마리서치바이오 (PharmaResearch Bio Co., Ltd.)
Websiteurl
pr-bio.co.kr
Company typeenum
Private
Founded yearint
2009
Descriptiontext

PharmaResearch Bio Co., Ltd. (주식회사 파마리서치바이오) is a Korean biopharmaceutical company founded in 2009 (originally as BIOCND Co., Ltd., renamed in 2018) that specializes exclusively in botulinum toxin products for aesthetic and therapeutic applications. The company operates as a subsidiary of PharmaResearch (파마리서치), is listed on the KONEX market (since 2015), and is headquartered with a GMP-certified manufacturing facility in Gangneung, Gangwon-do, while R&D activities are conducted from a Seongnam, Gyeonggi-do laboratory. As of 2025 the company has 77 regular employees. PharmaResearch Bio's product portfolio centers on two commercialized SKUs: Re N Tox Inj 100 units for the domestic Korean market (MFDS-approved February 2024, commercial launch April 2025) and Re N Tox in 100- and 200-unit formulations for export markets. The company's proprietary technology stack includes botulinum toxin protein purification achieving 99.97% purity for the 900kDa complex, purification of the 150kDa pure neurotoxin, and a Polynucleotide (PN) bio-persistence enhancement that extends muscle relaxation duration up to 2.3x. A pipeline of four next-generation candidates (BCD200 with Phase 3 completed in 2021, PRB004 liquid-type, PRB002 150kDa, PRB005 next-generation) and a PN Calcium Filler composition expand the franchise beyond the lead toxin.

The business model is B2B prescription pharmaceutical distribution through enterprise field sales targeting medical aesthetic clinics, dermatology clinics, and hospitals. Domestically, products move through prescription channels requiring medical professional authorization; internationally, distribution targets Thailand (where TFDA approval was secured in August 2025), Southeast Asia, and prospective European markets. A second EU-GMP compliant manufacturing facility is under construction at the Gangneung Science Industrial Complex (7,905 sqm, completion targeted 2026, planned 6 million vials per year capacity), backed by a 193 billion KRW investment agreement with Gangneung City and Gangwon Province. The company has achieved the 10 Million Dollar Export Tower award in 2023, reflecting over 70% average annual revenue growth since the 2019 export initiation. The company is led by co-CEOs Baek Seung-gul and Dr. Won Ji-yeob (formerly of Roche, Johnson & Johnson, and Allergan).

Short descriptiontext

PharmaResearch Bio is a Korean biopharmaceutical subsidiary of PharmaResearch that develops, manufactures, and sells prescription botulinum toxin products (Re N Tox) for medical aesthetic clinics, dermatology clinics, and hospitals in domestic and export markets.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersGangneung, South Korea
HQ citystring
Gangneung
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
botulinum toxin products, aesthetic pharmaceuticals, biopharmaceutical manufacturing, prescription injectables, medical aesthetics drugs
Industry2 codes
PRIMARYHLAAAKAI
Raw Materials & Critical Reagents Supply Services (media, resins, single-use)
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers4242
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Aesthetic Biopharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Botulinum Toxin Product Sales
TypeOne Time License
Description

Sale of botulinum toxin pharmaceutical products including Re N Tox (domestic use) and Re N ToxS (export use) in 100-unit and 200-unit formulations.

pr-bio.co.kr
2Pharmaceutical Product Licensing
TypeLicensing Royalties
Description

Revenue from obtaining product approvals and licensing botulinum toxin products for global markets.

pr-bio.co.kr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Infrastructure, Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Re N Tox®주 (내수용)
Description

Botulinum toxin product for domestic use, 100 units, indicated for temporary improvement of moderate to severe glabellar lines.

pr-bio.co.kr
+1 more record
Core offering1 text field

PharmaResearch Bio manufactures and sells prescription Clostridium botulinum toxin Type A injectable products (Re N Tox Inj 100 units for domestic Korean use and Re N Tox 100/200 units for export) for the temporary improvement of moderate to severe glabellar lines in adults aged 19–65. The company produces these sterile injectables at its GMP-certified Gangneung facility, supported by a vertically integrated pipeline spanning botulinum toxin cultivation, purification (99.97% purity), and proprietary PN-enhanced formulation, and is expanding export distribution to markets including Thailand and broader Southeast Asia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 99.97% purity achieved in botulinum toxin protein purification
+3 more records
Product overview1 text field

PharmaResearch Bio is a biopharmaceutical company specializing in botulinum toxin-based pharmaceuticals for aesthetic and therapeutic applications. The company operates two marketed products: Re N Tox Inj (domestic use, 100 units) and Re N Tox (export use, 100 and 200 units), both containing Clostridium botulinum toxin Type A for temporary improvement of moderate to severe glabellar lines. The product portfolio is supported by a pipeline of next-generation botulinum toxin formulations (BCD200 in Phase 3, PRB004/002/005 in earlier stages) and broader biotech C&D (Connect & Development) initiatives including dermal fillers. The company operates GMP-certified manufacturing facilities in Gangneung, South Korea, and is expanding production capacity with a second plant (EU-GMP standard) targeting 6 million vials per year by 2026.

Product and service2 records
1Re N Tox Inj (리엔톡주) – Domestic Use
CategoryAesthetic Botulinum Toxin Injectable
Description

Prescription Clostridium botulinum toxin Type A injectable (100 units) for the domestic Korean market, indicated for temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults aged 19–65. Distributed as a sealed vial, stored refrigerated at 2–8°C, with a 36-month shelf life; sold through prescription-based channels to Korean medical institutions.

2Re N Tox (리엔톡스주) – Export Use
CategoryAesthetic Botulinum Toxin Injectable
Description

Prescription Clostridium botulinum toxin Type A injectable for international export markets, available in 100-unit and 200-unit formulations. Indicated for temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults aged 19–65; sold through prescription-based export channels to medical institutions in approved territories.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Yojin Construction Industry (요진건설산업)
Strategic tierMinorTypeOthersAnnounced on2023-09-22
Description

Construction partnership for building the second factory facility. Yojin Construction Industry was contracted to construct the 7,905㎡ manufacturing facility at Gangneung Science Industrial Complex, scheduled for completion in 2026.

pr-bio.co.kr
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-08
Description

Investment agreement for factory expansion. Gangneung City and Gangwon Province partnered with PharmaResearch Bio for the Gangneung factory expansion project, providing administrative support and investment incentives for the 193 billion KRW project.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AbbVie acquired Allergan in 2020 and markets Botox, the dominant global botulinum toxin brand. While a massive diversified pharma, Botox remains the gold-standard neurotoxin against which all competitors including PharmaResearch Bio's Re N Tox are benchmarked in aesthetic and therapeutic indications.

TypeBroad incumbent
Description

French pharmaceutical company that markets Dysport (abobotulinumtoxinA), one of the leading botulinum toxin brands globally. Competes directly with PharmaResearch Bio in aesthetic and therapeutic neurotoxin indications with established distribution networks across Europe and other markets.

TypeBroad incumbent
Description

Merz markets Xeomin/Bocouture (incobotulinumtoxinA), a major botulinum toxin competitor. As a broader aesthetics player with portfolio spanning fillers and toxins, it competes with PharmaResearch Bio in the aesthetic neurotoxin market with similar clinic-channel GTM approach.

TypeDirect peer
Description

Korean botulinum toxin manufacturer marketing Botulax/Letybo - the most directly comparable Korean competitor to PharmaResearch Bio. Hugel has established global export presence and competes head-to-head in similar Asian and international markets with comparable go-to-market and regulatory strategies.

TypeDirect peer
Description

Korean pharmaceutical company marketing Nabota (prabotulinumtoxinA), a directly competitive botulinum toxin. Like PharmaResearch Bio, Daewoong has pursued international approvals and competes in both domestic Korean and global neurotoxin markets with similar product positioning.

TypeDirect peer
Description

Korean botulinum toxin manufacturer known for Meditoxin/A型 products. A direct competitor in the Korean and Asian botulinum toxin markets, operating in the same product category and targeting similar medical aesthetic and therapeutic use cases as PharmaResearch Bio.

7Evolus
TypeDirect peer
Description

US-based aesthetic pharmaceutical company focused on neurotoxins, marketing Jeuveau (prabotulinumtoxinA-xvfs). Pure-play aesthetic neurotoxin competitor with highly comparable go-to-market focus on medical aesthetic clinics and dermatology practices - very similar business model to PharmaResearch Bio's clinic-channel approach.

TypeBroad incumbent
Description

Global aesthetics-focused company (spun out from Nestlé) with portfolio including Restylane fillers and other aesthetic products. Broader incumbent in aesthetics, partnering with Ipsen on Azzalure distribution in some markets, and competing with PharmaResearch Bio's expanding portfolio of toxin and filler products.

9Revance Therapeutics
TypeEmerging player
Description

US company that launched Daxxify (daxibotulinumtoxinA-lanm), a next-generation botulinum toxin with longer duration claims. Represents emerging competitive technology that could disrupt the standard botulinum toxin market where PharmaResearch Bio competes, especially if longer-duration claims drive share shifts.

10Croma-Pharma
TypeRegional player
Description

Austrian aesthetic pharmaceutical company distributing Azzalure botulinum toxin in partnership with Ipsen across European markets. Provides a comparable European-focused specialty distribution model relevant to PharmaResearch Bio's planned EU-GMP expansion and serves as a regional specialist benchmark.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharma Research Bio

Aesthetic Biopharmaceuticalspr-bio.co.kr

PharmaResearch Bio is a Korean biopharmaceutical subsidiary of PharmaResearch that develops, manufactures, and sells prescription botulinum toxin products (Re N Tox) for medical aesthetic clinics, dermatology clinics, and hospitals in domestic and export markets.

What Pharma Research Bio does

PharmaResearch Bio Co., Ltd. (주식회사 파마리서치바이오) is a Korean biopharmaceutical company founded in 2009 (originally as BIOCND Co., Ltd., renamed in 2018) that specializes exclusively in botulinum toxin products for aesthetic and therapeutic applications. The company operates as a subsidiary of PharmaResearch (파마리서치), is listed on the KONEX market (since 2015), and is headquartered with a GMP-certified manufacturing facility in Gangneung, Gangwon-do, while R&D activities are conducted from a Seongnam, Gyeonggi-do laboratory. As of 2025 the company has 77 regular employees. PharmaResearch Bio's product portfolio centers on two commercialized SKUs: Re N Tox Inj 100 units for the domestic Korean market (MFDS-approved February 2024, commercial launch April 2025) and Re N Tox in 100- and 200-unit formulations for export markets. The company's proprietary technology stack includes botulinum toxin protein purification achieving 99.97% purity for the 900kDa complex, purification of the 150kDa pure neurotoxin, and a Polynucleotide (PN) bio-persistence enhancement that extends muscle relaxation duration up to 2.3x. A pipeline of four next-generation candidates (BCD200 with Phase 3 completed in 2021, PRB004 liquid-type, PRB002 150kDa, PRB005 next-generation) and a PN Calcium Filler composition expand the franchise beyond the lead toxin.

The business model is B2B prescription pharmaceutical distribution through enterprise field sales targeting medical aesthetic clinics, dermatology clinics, and hospitals. Domestically, products move through prescription channels requiring medical professional authorization; internationally, distribution targets Thailand (where TFDA approval was secured in August 2025), Southeast Asia, and prospective European markets. A second EU-GMP compliant manufacturing facility is under construction at the Gangneung Science Industrial Complex (7,905 sqm, completion targeted 2026, planned 6 million vials per year capacity), backed by a 193 billion KRW investment agreement with Gangneung City and Gangwon Province. The company has achieved the 10 Million Dollar Export Tower award in 2023, reflecting over 70% average annual revenue growth since the 2019 export initiation. The company is led by co-CEOs Baek Seung-gul and Dr. Won Ji-yeob (formerly of Roche, Johnson & Johnson, and Allergan).

Pharma Research Bio firmographics

Firmographics
Name
Pharma Research Bio
Legal name
주식회사 파마리서치바이오 (PharmaResearch Bio Co., Ltd.)
Website
https://pr-bio.co.kr
Company type
Private
Founded year
2009
Operating status
Operating
Short description
PharmaResearch Bio is a Korean biopharmaceutical subsidiary of PharmaResearch that develops, manufactures, and sells prescription botulinum toxin products (Re N Tox) for medical aesthetic clinics, dermatology clinics, and hospitals in domestic and export markets.
Ownership category
akta.pro rank

Pharma Research Bio industry classification

Industry
Product category
Aesthetic Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (4242)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAAAKAI
Raw Materials & Critical Reagents Supply Services (media, resins, single-use)
SECONDARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Botulinum toxin products
  • Aesthetic pharmaceuticals
  • Biopharmaceutical manufacturing
  • Prescription injectables
  • Medical aesthetics drugs

Where Pharma Research Bio is headquartered

Location

Headquarters

HQ city
Gangneung
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Pharma Research Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Infrastructure, Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Botulinum Toxin Product Sales: Sale of botulinum toxin pharmaceutical products including Re N Tox (domestic use) and Re N ToxS (export use) in 100-unit and 200-unit formulations.
  2. Pharmaceutical Product Licensing: Revenue from obtaining product approvals and licensing botulinum toxin products for global markets.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Pharma Research Bio product offering

Product offering

Core offering

PharmaResearch Bio manufactures and sells prescription Clostridium botulinum toxin Type A injectable products (Re N Tox Inj 100 units for domestic Korean use and Re N Tox 100/200 units for export) for the temporary improvement of moderate to severe glabellar lines in adults aged 19–65. The company produces these sterile injectables at its GMP-certified Gangneung facility, supported by a vertically integrated pipeline spanning botulinum toxin cultivation, purification (99.97% purity), and proprietary PN-enhanced formulation, and is expanding export distribution to markets including Thailand and broader Southeast Asia.

Product overview

PharmaResearch Bio is a biopharmaceutical company specializing in botulinum toxin-based pharmaceuticals for aesthetic and therapeutic applications. The company operates two marketed products: Re N Tox Inj (domestic use, 100 units) and Re N Tox (export use, 100 and 200 units), both containing Clostridium botulinum toxin Type A for temporary improvement of moderate to severe glabellar lines. The product portfolio is supported by a pipeline of next-generation botulinum toxin formulations (BCD200 in Phase 3, PRB004/002/005 in earlier stages) and broader biotech C&D (Connect & Development) initiatives including dermal fillers. The company operates GMP-certified manufacturing facilities in Gangneung, South Korea, and is expanding production capacity with a second plant (EU-GMP standard) targeting 6 million vials per year by 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • Re N Tox®주 (내수용): Botulinum toxin product for domestic use, 100 units, indicated for temporary improvement of moderate to severe glabellar lines.
  • Re N Tox™ (수출용)

Products and services

  • Re N Tox Inj (리엔톡주) – Domestic Use Prescription Clostridium botulinum toxin Type A injectable (100 units) for the domestic Korean market, indicated for temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults aged 19–65. Distributed as a sealed vial, stored refrigerated at 2–8°C, with a 36-month shelf life; sold through prescription-based channels to Korean medical institutions.
  • Re N Tox (리엔톡스주) – Export Use Prescription Clostridium botulinum toxin Type A injectable for international export markets, available in 100-unit and 200-unit formulations. Indicated for temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults aged 19–65; sold through prescription-based export channels to medical institutions in approved territories.

Quantifiable outcome

  • 99.97% purity achieved in botulinum toxin protein purification
  • +3 more outcomes

Companies that use Pharma Research Bio

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Pharma Research Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pharma Research Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Yojin Construction Industry (요진건설산업)minorOthers · 22 September 2023Construction partnership for building the second factory facility. Yojin Construction Industry was contracted to construct the 7,905㎡ manufacturing facility at Gangneung Science Industrial Complex, scheduled for completion in 2026.
  • Gangneung City and Gangwon Province (강릉시·강원도)coreStrategic or Co-development Partner · 8 June 2023Investment agreement for factory expansion. Gangneung City and Gangwon Province partnered with PharmaResearch Bio for the Gangneung factory expansion project, providing administrative support and investment incentives for the 193 billion KRW project.

Scale indicators6 records

Recent moves12 records

Expansion highlights5 records

Pharma Research Bio competitors and assessment

Company assessment

Broad incumbents

  • AbbVie (Allergan Aesthetics): AbbVie acquired Allergan in 2020 and markets Botox, the dominant global botulinum toxin brand. While a massive diversified pharma, Botox remains the gold-standard neurotoxin against which all competitors including PharmaResearch Bio's Re N Tox are benchmarked in aesthetic and therapeutic indications.
  • Ipsen: French pharmaceutical company that markets Dysport (abobotulinumtoxinA), one of the leading botulinum toxin brands globally. Competes directly with PharmaResearch Bio in aesthetic and therapeutic neurotoxin indications with established distribution networks across Europe and other markets.
  • Merz Aesthetics: Merz markets Xeomin/Bocouture (incobotulinumtoxinA), a major botulinum toxin competitor. As a broader aesthetics player with portfolio spanning fillers and toxins, it competes with PharmaResearch Bio in the aesthetic neurotoxin market with similar clinic-channel GTM approach.
  • Galderma: Global aesthetics-focused company (spun out from Nestlé) with portfolio including Restylane fillers and other aesthetic products. Broader incumbent in aesthetics, partnering with Ipsen on Azzalure distribution in some markets, and competing with PharmaResearch Bio's expanding portfolio of toxin and filler products.

Direct peers

  • Hugel: Korean botulinum toxin manufacturer marketing Botulax/Letybo - the most directly comparable Korean competitor to PharmaResearch Bio. Hugel has established global export presence and competes head-to-head in similar Asian and international markets with comparable go-to-market and regulatory strategies.
  • Daewoong Pharmaceutical: Korean pharmaceutical company marketing Nabota (prabotulinumtoxinA), a directly competitive botulinum toxin. Like PharmaResearch Bio, Daewoong has pursued international approvals and competes in both domestic Korean and global neurotoxin markets with similar product positioning.
  • Medytox: Korean botulinum toxin manufacturer known for Meditoxin/A型 products. A direct competitor in the Korean and Asian botulinum toxin markets, operating in the same product category and targeting similar medical aesthetic and therapeutic use cases as PharmaResearch Bio.
  • Evolus: US-based aesthetic pharmaceutical company focused on neurotoxins, marketing Jeuveau (prabotulinumtoxinA-xvfs). Pure-play aesthetic neurotoxin competitor with highly comparable go-to-market focus on medical aesthetic clinics and dermatology practices - very similar business model to PharmaResearch Bio's clinic-channel approach.

Emerging players

  • Revance Therapeutics: US company that launched Daxxify (daxibotulinumtoxinA-lanm), a next-generation botulinum toxin with longer duration claims. Represents emerging competitive technology that could disrupt the standard botulinum toxin market where PharmaResearch Bio competes, especially if longer-duration claims drive share shifts.

Regional players

  • Croma-Pharma: Austrian aesthetic pharmaceutical company distributing Azzalure botulinum toxin in partnership with Ipsen across European markets. Provides a comparable European-focused specialty distribution model relevant to PharmaResearch Bio's planned EU-GMP expansion and serves as a regional specialist benchmark.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Pharma Research Bio compliance and trust

Trust signal

Compliance1 record

Pharma Research Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharma Research Bio leadership team

Management profile

Number of profiles

Profiles4 records

Pharma Research Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharma Research Bio M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharma Research Bio

What does Pharma Research Bio do?

PharmaResearch Bio manufactures and sells prescription Clostridium botulinum toxin Type A injectable products (Re N Tox Inj 100 units for domestic Korean use and Re N Tox 100/200 units for export) for the temporary improvement of moderate to severe glabellar lines in adults aged 19–65. The company produces these sterile injectables at its GMP-certified Gangneung facility, supported by a vertically integrated pipeline spanning botulinum toxin cultivation, purification (99.97% purity), and proprietary PN-enhanced formulation, and is expanding export distribution to markets including Thailand and broader Southeast Asia.

Is Pharma Research Bio a public or private company?

Pharma Research Bio is a private company. It is classified as corporate owned and is currently operating.

When was Pharma Research Bio founded?

Pharma Research Bio was founded in 2009.

Where is Pharma Research Bio based?

Pharma Research Bio is headquartered in Gangneung, South Korea, in the Asia region.

How does Pharma Research Bio make money?

Two revenue lines are on record. Botulinum Toxin Product Sales are the primary driver. The others are pharmaceutical Product Licensing.

Who are Pharma Research Bio's main competitors?

Broad incumbents on record are AbbVie (Allergan Aesthetics), Ipsen, Merz Aesthetics and Galderma. Direct peers are Hugel, Daewoong Pharmaceutical, Medytox and Evolus. Revance Therapeutics is listed as an emerging player. Croma-Pharma is listed as a regional player.

Does Pharma Research Bio have an API?

No public API is recorded for Pharma Research Bio.

What industry is Pharma Research Bio in?

Pharma Research Bio's product category is Aesthetic Biopharmaceuticals. Its primary akta.pro industry code is HLAAAKAI, Raw Materials & Critical Reagents Supply Services (media, resins, single-use), with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire APACREJURAN COSMETICS Expands Across Canada with Nationwide Sephora LaunchREJURAN COSMETICS will launch nationwide across all 148 Sephora Canada stores on Sept. 1, featuring eight products including two hero ampoules. The brand uses PharmaResearch's proprietary c-PDRN™ technology, and the launch supports its North American expansion strategy.SedailyK-Aesthetics Firms Expand Portfolios Through Investment and M&AKorean aesthetic medicine companies Pharma Research, Hugel, and Jetema are accelerating portfolio expansion through investment and M&A to move beyond single-product revenue structures centered on toxins and fillers. Pharma Research disclosed plans to pursue M&A in medical devices and cosmetics to reduce dependence on its Rejuran skin booster, while Hugel signed a distribution agreement with Hans Biomed for an ECM-based skin booster and Jetema partnered with Hanmi Pharmaceutical to repurpose a joint treatment product for cosmetic use. The strategic moves come as intensifying competition from new entrants including ECM skin booster manufacturers and cosmetics companies entering the medical device market is pressuring established players to expand their product lines.PlatumConnect, Series C raises 15 billion won... Pharma Research participates as a strategic investorKonnex, a specialty biopharmaceutical development company, has completed a 15 billion won Series C funding round with participation from existing investor ES Investors, new financial investors Premier Partners, Murex Partners, Suin Investment Capital, and The Next Lab, alongside strategic investor Pharma Research. The strategic partnership with Pharma Research extends beyond their existing licensing agreement for core pipeline CNT201 into a share-based long-term collaboration combining Konnex's recombinant protein technology with Pharma Research's global commercialization capabilities. The funds will support Phase 2 clinical trials for Dupuytren's contracture treatment in Australia and preparation for global Phase 3 trials.Dove Medical PressExpert Perspectives: Evidence-Based Applications of Polynucleotides (PAn international panel of dermatologists has published an expert opinion article detailing the clinical applications and treatment protocols for polynucleotides (PNs) in aesthetic medicine. The review highlights the efficacy of PNs, specifically the Rejuran® product by PharmaResearch Co., Ltd, for indications including skin rejuvenation, structural support, barrier repair in rosacea and eczema, and scar remodeling. While demonstrating a favorable safety profile and biocompatibility, the authors note that further randomized controlled trials are needed to validate mechanisms and standardize usage.